According to findings released by GlobalData Healthcare (9 July, 2020) disruption caused to clinical trials by the COVID-19 pandemic is beginning to ease slightly. After three months of increasing disruptions to trials largely attributed to suspended enrolment there is some evidence of green shoots.
Trials that were disrupted due to suspended enrolment are showing signs of recovery (disruption down 17.3% compared to last month). However, clinical trials that delayed initiation have gone up 10% and trials that have been impacted by slow enrolment have gone up by 13.9% in the same period. The findings suggest that those trials that were already up and running (with sites and investigators already attached) but paused due to COVID-19 have had more success in restarting than trials seeking to start from scratch.
Another report released last week by clinical trial technology company Medidata found that the numbers of participants enrolling in trials had increased 112% in June when compared with April data. The research found that numbers were still down 30% on figures pre-pandemic and while there are signs of recovery rising numbers of COVID-19 cases in the US are likely to impact further on clinical trials being carried out there. The research by Medidata and reported by Reuters found that some of the biggest increases in numbers were in Europe while US trials have experienced less of a rebound. The report also notes that oncology trials have been impacted to a lesser degree and cardiovascular trials the most.
Ukraine, the eight largest European country by population, is an attractive location for sponsors conducting clinical research for a number of key reasons. Cromos Pharma has been successfully managing clinical trials in Ukraine since 2006. This article looks at just some of the benefits of locating your next study here.
Cromos Pharma is continuously developing and looking to explore new territories when it comes to clinical research. In line with this spirit of discovery, we will be shortly commencing a new project in Uzbekistan supporting a study being conducted by the Swiss Tropical and Public Health Institute.
Cromos Pharma is delighted to be taking part in the upcoming DIA Europe conference (15 – 19 March 2021) and BIO-Europe Spring (22-25 March 2021).
February 11th is International Women and Girls in Science Day. A joint UNESCO and UN-Women initiative, it aims to promote the role of #WomenInScience and to challenge some of the barriers to girls pursuing a career in science.
Are you a sponsor seeking to conduct clinical trials in the European Union but do not have a registered office in the European Economic Area? If so, in order to comply with the European Union Clinical Trial Directive, you are required to work with a Legal Representative registered in an EEA country.
Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer. World Cancer Day was established in Paris at the first World Cancer Summit in 2000.
As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies. The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data compiled by Bloomberg ( updated 7 Jan 2021).
Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus.
If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking here. The webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP.